2018 Top Story- Archives -
The single-minded goal of cardiologist and scientist Jane Freedman, MD, is to seek insights that will help heal patients with heart disease. Learn about her research and career in the latest Women in Science video.
Axovant Sciences, a Swiss company developing gene therapies for neurological diseases, has licensed exclusive worldwide rights for the development and commercialization of two novel gene therapy programs for Tay-Sachs and Sandhoff diseases from UMassMedical School.
Led by Guangping Gao, PhD, and Erik Sontheimer, PhD, scientists at UMass Medical School will work to develop technology to enable safe genome editing in patients, thanks to new grant funding from the National Institutes of Health.
Jeanne Lawrence, PhD, and Jaime Rivera, PhD, received a five-year, $2.8 million grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development at the National Institutes of Health to test a strategy in a mouse model for silencing the extra chromosome that causes Down Syndrome.
Victor Ambros, PhD, has been elected by his peers as a fellow of the American Association for the Advancement of Science.
A new study by Anastasia Khvorova, PhD, and Melissa Moore, PhD, at UMass Medical School and colleagues at Beth Israel Deaconess Medical Center and Western Sydney University, suggests that RNA interference therapy could be a potential strategy for the treatment of preeclampsia.
Matilde Castiel, MD, and Naheed Usmani, MD, shared their personal journeys of coming to the United States at the debut of the UMass Immigrant Stories series on Wednesday, Nov. 14.
The Substance Abuse and Mental Health Services Administration has awarded a grant to UMass Medical School to create a training program that will qualify medical, nurse practitioner and physician assistant students to provide medication-assisted treatment for opioid-addicted patients. Daniel Mullin, PsyD, is principal investigator on the grant.
The Toronto-based Blu Genes Foundation, which is dedicated to developing gene therapies for rare disease, has given $1.4 million to UMass Medical School to advance a Phase I/II clinical trial for Tay-Sachs. Miguel Sena-Esteves, PhD, Terence Flotte, MD, Heather Gray-Edwards, PhD, DVM, and colleagues at Auburn University are leading the research.
The annual Commonwealth of Massachusetts Employee Charitable Campaign kicks off at UMass Medical School on Monday, Nov. 5. The statewide campaign allows UMMS employees to contribute to any of more than 1,000 screened nonprofit organizations that support a wide range of needs.